Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

NCTID	NCT04124042 (View at clinicaltrials.gov)
Description	This is a Phase 2 safety and efficacy study of XT-150 in adult participants experiencing moderate to severe pain due to osteoarthritis of the knee. (Show More)
Development Status	Active
Indication	Osteoarthritis, Knee
Disease Ontology Term	DOID:8398
Compound Name	XT-150
Sponsor	Xalud Therapeutics, Inc.
Funder Type	Industry
Recruitment Status	Completed
Enrollment Count	289
Results Posted	View Results

Target Gene/Variant	Recombinant IL10
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intraarticular
Drug Product Type	Plasmid
Target Tissue/Cell
Delivery System	None (naked plasmid)
Vector Type
Editor Type
Dose 1	150ug
Dose 2	450ug (extension study)
Dose 3
Dose 4
Dose 5

No.of Trial Sites	6
Locations	United States,Australia